BioClinica enters five-year enterprise-wide agreement for Optimizer technology

BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, today announced that a Top Ten pharmaceutical company has entered into a five-year enterprise-wide agreement for BioClinica Optimizer to simulate and forecast clinical trial supply scenarios for their worldwide clinical trial operations. BioClinica Optimizer was selected for its flexibility to simulate and optimize large-scale, complex clinical trials while remaining cost effective for smaller, early phase studies.

“Progressive companies seek the best available tools to design and support the complex logistics associated with global clinical trials. Six of the Top 10 pharmaceutical and biotech companies now use BioClinica Optimizer technology, with savings measured in millions of dollars.”

BioClinica Optimizer is the world's only clinical trial supply forecasting tool that both simulates and optimizes clinical supply chains. "Our mission is to offer best-in-class products and services to our customers," said Peter Benton, President of BioClinica's eClinical division. "Progressive companies seek the best available tools to design and support the complex logistics associated with global clinical trials. Six of the Top 10 pharmaceutical and biotech companies now use BioClinica Optimizer technology, with savings measured in millions of dollars."

"This selection exemplifies client validation of our eClinical strategy," said Mark Weinstein, CEO of BioClinica. "This organization was already a large imaging services client; now BioClinica will support new areas of their clinical trial processes. The client told us that with BioClinica Optimizer they anticipate better information for designing studies with faster study starts, a reduction in patient participation drop-off, reduced waste and overstocking and an overall cost savings with improved supply management. This is a win for both organizations."